Document is current
Any future updates will be listed below
-
Authors
Locatelli, Francesco https://orcid.org/0000-0002-7505-261X
Ravera, Maura https://orcid.org/0000-0003-3856-6168
Esposito, Ciro https://orcid.org/0000-0002-7906-1097
Grandaliano, Giuseppe https://orcid.org/0000-0003-1213-2177
Gesualdo, Loreto https://orcid.org/0000-0002-4861-0911
Minutolo, Roberto https://orcid.org/0000-0001-5686-2089
-
Funding
Funding for this research was provided by:
Astellas
- License Information
-
More Information
Article History
Received: 16 June 2023
Accepted: 23 November 2023
First Online: 8 January 2024
Declarations
:
: Francesco Locatelli is or was a member of an advisory board of Amgen and Vifor Pharma; and was a speaker at meetings supported by Amgen, Astellas, and Vifor Pharma. Maura Ravera has been a member of advisory boards for Astellas and GSK; and an invited speaker at meetings supported by Amgen, Astellas, Vifor Pharma, and AstraZeneca. Ciro Esposito has been a member of advisory boards for Amgen, Astellas, and GSK; and an invited speaker at meetings supported by Astellas, AstraZeneca, GSK, and Vifor Pharma. Roberto Minutolo has been a member of advisory boards for Amgen, Astellas, and GSK; has received consulting fees from Bayer and GSK; and has been an invited speaker at meetings supported by Amgen, Astellas, Vifor Pharma, and AstraZeneca. Loreto Gesualdo has received research grants from Abionyx and Sanofi; and speaking and consulting fees from AstraZeneca, Baxter, Chinook, GSK, Medtronic, Mundipharma, Novartis, Pharmadoc, Roche, Sandoz, Sanofi, Travere, Astellas, Estor, Fresenius and Werfen. Giuseppe Grandaliano has no conflicts of interest to declare.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: For this type of study, formal consent is not required.
: Not applicable.
: Not applicable.
: Not applicable.
